Green Paula sold 20,429 shares of TWST

Green Paula (SVP of Human Resources) sold 20,429 shares of Twist Bioscience Corp (TWST) on 2026-11-12.

Original reporting
SEC EDGAR · Green Paula
Published Nov 16, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosure updates insider activity records for TWST but does not introduce new business, financial, or regulatory information.

02

Market read

Traders may briefly reassess sentiment around TWST due to insider selling, but the lack of disclosed transaction value and absence of operational news reduces tradable impact.

03

What to watch

No 10b5-1 plan is stated, but the article also lacks context on total holdings, prior sales cadence, and whether the sale was tax-related or pre-scheduled outside a 10b5-1 plan.

Relevance 4/10Novelty 4/10Timing: filed after-hours on 2026-11-16, referencing a 2026-11-12 sale

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Twist Bioscience.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience disclosed an insider open-market sale of 20,429 shares by SVP of Human Resources Green Paula on 2026-11-12.

Expected impact

Likely limited near-term impact, with any reaction more sentiment-driven than fundamentals-driven.

Evidence & confidence

This is a Form 4 insider transaction with undisclosed sale price/value; without a 10b5-1 plan, traders may scrutinize timing, but the article lacks magnitude in dollars and provides no operational or guidance catalyst.

Market effects

Minimal, as this is company-specific insider selling with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity management rather than a bearish signal, especially since the filing does not disclose sale price or total proceeds.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider transaction disclosure.

  • Green Paula

    SVP of Human Resources who sold 20,429 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHighAI 8/10

Canaccord cuts Twist Bioscience stock price target on lower revenue outlook

Canaccord reduced Twist Bioscience's (TWST) price target to $150 from $205, citing lower long-term revenue estimates. The company's Q4 results beat expectations, with revenue up 28% YoY to $126.6M. Twist provided fiscal 2027 guidance ahead of consensus but expects slower AI-enabled drug discovery revenue growth. Jefferies also lowered its target to $125, maintaining a Hold rating. TWST shares are down in premarket trading.

$TWSTHighAI 8/10

Twist Bioscience Corporation Q4 2026 Earnings Call Summary

Twist Bioscience reported positive adjusted EBITDA in Q4 2026, with revenue growth driven by a 175% YoY increase in AI drug discovery. The company expects $550M-$560M revenue in 2027, with $100M from AI drug discovery. It plans $150M in CapEx over two years to support future growth. Management highlighted structural advantages and strategic initiatives in AI and nucleic acid therapeutics.

$TWSTMedAI 8/10

Twist Bioscience Q4 Earnings Call Highlights

Twist Bioscience reported shipping 401,000 genes in Q4 and 1.3 million for the year. AI drug discovery revenue rose 175% to $59.1M. The company plans to expand capacity with 16 DNA writers and invest $150M in capital expenditures. Twist expects fiscal 2027 revenue of $130M-$132M in Q1 and positive adjusted EBITDA.

$TWSTMedAI 8/10

Twist Bioscience earnings analysis: questions answered and next catalysts

Twist Bioscience (TWST) reported FY2026 Q4 earnings on Nov 12, 2026, beating EPS and revenue estimates. Despite this, shares fell 7.90% to $112.91. Revenue grew 28% YoY to $126.6M, and the company achieved positive adjusted EBITDA of $2.2M. Management provided FY2027 guidance of $550M–$560M in revenue, above consensus. Concerns include valuation, capital intensity, and reliance on AI drug discovery orders. Next catalysts include Q1 FY2027 results and AI updates.